---
title: "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294692386.md"
description: "The RESTORE-FA trial is advancing with modifications following promising results after four weeks of dosing. The forthcoming data, based on 12 weeks of dosing, is anticipated to be unveiled in the first quarter of 2027."
datetime: "2026-08-03T12:03:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294692386.md)
  - [en](https://longbridge.com/en/news/294692386.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294692386.md)
---

# Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

The RESTORE-FA trial is advancing with modifications following promising results after four weeks of dosing. The forthcoming data, based on 12 weeks of dosing, is anticipated to be unveiled in the first quarter of 2027.

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)

## Related News & Research

- [Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million](https://longbridge.com/en/news/294690302.md)
- [First Advantage (FA) On Strong Earnings And Higher Guidance Faces A Fresh Valuation Test](https://longbridge.com/en/news/295147170.md)
- [Lenz Therapeutics schedules webcast to report Q2 2026 results](https://longbridge.com/en/news/294867529.md)
- [First Advantage Co. (NYSE:FA) Given Average Recommendation of "Hold" by Analysts](https://longbridge.com/en/news/294717381.md)
- [Needham & Company LLC Upgrades First Advantage (NYSE:FA) to Buy](https://longbridge.com/en/news/295132462.md)